stat-ins

Are external control arms worth the extra effort?

Are external control arms worth the extra effort?
Are external control arms worth the extra effort? 558 344 Exploristics

By Exploristics CDSO, Kimberley Hacquoil

The FDA have recently published a draft guidance for the design and conduct of externally controlled trials which specifically focuses on the use of patient level data as a full external control arm. This external …

It’s not rare to have a rare disease

It’s not rare to have a rare disease
It’s not rare to have a rare disease 558 344 Exploristics

By Exploristics Chief Data Scientific Officer, Kimberley Hacquoil

It’s estimated that 300 million people worldwide are living with a rare disease and 85% – 90% of these are considered “serious or life threatening”. Even though there has been huge progress

…
Pharma’s Road to Damascus? Learnings from the COVID-19 Pandemic

Pharma’s Road to Damascus?
Pharma’s Road to Damascus? 558 344 Exploristics

By Exploristics CEO, Aiden Flynn.

For many years, the pharmaceutical industry has faced an ongoing challenge of trying to improve the speed, efficiency and profitability of drug development despite rising R&D costs. Then in 2020, the COVID-19 pandemic hit. Not …

Synthetic Control Arms: Making the leap beyond the gold standard

Synthetic Control Arms: Making the leap beyond the gold standard
Synthetic Control Arms: Making the leap beyond the gold standard 558 344 Exploristics

by Exploristics Chief Data Scientific Officer Kimberley Hacquoil

Drug development is difficult and it’s only going to get harder. The cost of drug development continues to increase, the time to get investigational treatments to patients is longer, and the path …

Connections and correlations, interactions and interrelationships.

Connections and correlations, interactions and interrelationships.
Connections and correlations, interactions and interrelationships. 558 344 Exploristics

By Exploristics Chief Data Scientific Officer Kimberley Hacquoil

We live in an interconnected society where nothing in life exists in complete isolation. Everywhere we look there are things interacting with other things. For example, how are you feeling as you …

Interactive visualisations are the future for effective collaborations

Interactive visualisations are the future for effective collaborations
Interactive visualisations are the future for effective collaborations 558 344 Exploristics

by Exploristics Chief Data Scientific Officer Kimberley Hacquoil

Humans are visual beings with an image being processed around 60,000 times faster than any form of text. It’s therefore not surprising that effective visualisations are a vital way to relay information …

Daring to be Different

Daring to be Different
Daring to be Different 558 344 Exploristics

By Dr Aiden Flynn, Exploristics CEO

I founded Exploristics in April 2009 with a vision of how biostatistics could be better harnessed to support more ground-breaking clinical research and development. Over 13 years later, Exploristics continues to grow with teams …

PSI Conference 2022, Gothenburg Sweden

PSI Conference 2022
PSI Conference 2022 558 344 Exploristics

By Alecia Nickless, PhD, Principal Statistician at Exploristics

The first in-person PSI Conference since the start of the COVID-19 pandemic was held last month at the Gothia Towers in Gothenburg, Sweden. From the record attendance, it was clear that PSI …

Counting the Costs of Clinical Trials: Why Rethinking Trial Design Matters

Counting the Costs of Clinical Trials
Counting the Costs of Clinical Trials 558 344 Exploristics

By Exploristics CEO – Aiden Flynn 

Clinical development is extremely costly, in terms of money, time and patient burden. Financially, the median cost of a clinical trial supporting FDA approval of a new drug is US$19M [1], while the …

Estimands – The “what” and the “how” of drug discovery

Estimands – The “what” and the “how” of drug discovery
Estimands – The “what” and the “how” of drug discovery 558 344 Exploristics

By Exploristics Chief Data Scientific Officer – Kimberley Hacquoil

In clinical development, clear, precise and transparent specification of the research question and associated treatment effects of interest are vital. This is especially crucial as trials often involve multiple stakeholders who …

what can we find for you?

We are thrilled to announce that Exploristics is now part of MMS, a global data-focused CRO!

Read more
X